Introduction: Cannabis (marijuana) use (medical) and abuse is becoming more and more common practice among different age groups in Israel. There is nearly no data regarding patients admitted to the medical ward with a positive urine test for marijuana. Research Methods: All the patients admitted to the medical ward at Laniado Hospital during the previous 3 years with positive urine test for marijuana were identified. Demographic, clinical and Lab parameters were documented. Patients were divided into 2 groups: Group 1 that had positive test for marijuana only and Group 2 that was positive also to other substance/s besides cannabis. A third group (Group 3), with a positive urine test for toxicology substance/s but negative for marijuana, was used as a control group. Research Results: Forty-nine patients in either Group 1 or Group 2 and 36 patients in Group 3 were documented. Patients from Groups 1 and 2 were significantly younger than those from Group 3. The most common cause of admission among these two groups was convulsions, while in Group 3, it was suicidal attempt. Group 2 patients, as opposed to Group 3 patients, included more patients with positive urine test for hard substances such as cocaine, amphetamines and ecstasy. More patients in Group 3 needed intubation with longer duration of hospital stay and one fatality. Conclusions: Positive tests for marijuana are not a rare phenomenon in our admitted patients. Most of the patients are young and admitted mainly to convulsions. These patients also used significantly more other hard substances than patients with positive test for substances other than cannabis.
References
[1]
Bar-Or, R.L., Kor, A., Jaljuli, I. and Lev-Ran, S. (2021) The Epidemiology of Substance Use Disorders among the Adult Jewish Population in Israel. European Addiction Research, 27, 362-370. https://doi.org/10.1159/000513776
[2]
Naftali, T., Bar Lev, L., Yablekovitz, D., Half, E. and Konikoff, F.M. (2011) Treatment of Crohn’s Disease with Cannabis: An Observational Study. The Israel Medical Association Journal, 13, 455-458.
[3]
Habib, G., Khazin, F. and Artul, S. (2021) The Effect of Medical Cannabis on Pain Level and Quality of Sleep among Rheumatology Clinic Outpatients. Pain Research and Management, 2021, 1-6. https://doi.org/10.1155/2021/1756588
[4]
Tuvel, A.L., Winiger, E.A. and Ross, J.M. (2023) A Review of the Effects of Adolescent Cannabis Use on Physical Health. Psychiatric Clinics of North America, 46, 719-739. https://doi.org/10.1016/j.psc.2023.03.005
[5]
Sharma, P. and Bharath, M.M. (2010) Qualitative High Performance Thin Layer Chromatography (HPTLC) Analysis of Cannabinoids in Urine Samples of Cannabis Abusers. Indian Journal of Medical Research, 132, 201-208.
[6]
Teherán, A.A., Pombo, L.M., Cadavid, V., Mejía, M.C., La Rota, J.F., Hernández, J.C., et al. (2019) Cocaine, Ethanol, Cannabis and Benzodiazepines Co-Consumption among Patients Assisted at the Emergency Room. Open Access Emergency Medicine: OAEM, 11, 211-219. https://doi.org/10.2147/OAEM.S197903
[7]
Weinberger, A.H., Zhu, J., Lee, J., Anastasiou, E., Copeland, J. and Goodwin, R.D. (2020) Cannabis Use among Youth in the United States, 2004-2016: Faster Rate of Increase among Youth with Depression. Drug and Alcohol Dependence, 209, Article ID: 107894. https://doi.org/10.1016/j.drugalcdep.2020.107894
[8]
Winward, J.L., Hanson, K.L., Tapert, S.F. and Brown, S.A. (2014) Heavy Alcohol Use, Marijuana Use, and Concomitant Use by Adolescents Are Associated with Unique and Shared Cognitive Decrements. Journal of the International Neuropsychological Society, 20, 784-795. https://doi.org/10.1017/s1355617714000666
[9]
Hefner, K., Sofuoglu, M. and Rosenheck, R. (2015) Concomitant Cannabis Abuse/Dependence in Patients Treated with Opioids for Non-Cancer Pain. The American Journal on Addictions, 24, 538-545. https://doi.org/10.1111/ajad.12260
[10]
Picton, J.D., Marino, A.B. and Nealy, K.L. (2018) Benzodiazepine Use and Cognitive Decline in the Elderly. American Journal of Health-System Pharmacy, 75, e6-e12. https://doi.org/10.2146/ajhp160381
[11]
Gaston, T.E. and Szaflarski, J.P. (2018) Cannabis for the Treatment of Epilepsy: An Update. Current Neurology and Neuroscience Reports, 18, Article No. 73. https://doi.org/10.1007/s11910-018-0882-y
[12]
Fitzgerald, K.T., Bronstein, A.C. and Newquist, K.L. (2013) Marijuana Poisoning. Topics in Companion Animal Medicine, 28, 8-12. https://doi.org/10.1053/j.tcam.2013.03.004
[13]
Zagnoni, P.G. and Albano, C. (2002) Psychostimulants and Epilepsy. Epilepsia, 43, 28-31. https://doi.org/10.1046/j.1528-1157.2002.043s2028.x
[14]
García-Gutiérrez, M.S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F. and Manzanares, J. (2020) Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. Biomolecules, 10, Article 1575. https://doi.org/10.3390/biom10111575
[15]
Pelkonen, M. and Marttunen, M. (2003) Child and Adolescent Suicide. Pediatric Drugs, 5, 243-265. https://doi.org/10.2165/00128072-200305040-00004
[16]
Hackam, D.G. (2015) Cannabis and Stroke. Stroke, 46, 852-856. https://doi.org/10.1161/strokeaha.115.008680
